Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXB for Autonomic Symptoms in IH and POTS
NCT07077278Phase 4Not yet recruiting
- Sponsor
- Stanford University
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in idiopathic hypersomnia (IH), postural orthostatic tachycardia syndrome (POTS), sponsored by Stanford University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
idiopathic hypersomnia (IH)postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT07077278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077278.